MX2017013433A - Composiciones antibacterianas. - Google Patents

Composiciones antibacterianas.

Info

Publication number
MX2017013433A
MX2017013433A MX2017013433A MX2017013433A MX2017013433A MX 2017013433 A MX2017013433 A MX 2017013433A MX 2017013433 A MX2017013433 A MX 2017013433A MX 2017013433 A MX2017013433 A MX 2017013433A MX 2017013433 A MX2017013433 A MX 2017013433A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
antibacterial compositions
tazobactam
cefepime
Prior art date
Application number
MX2017013433A
Other languages
English (en)
Inventor
Deo Keshav
Nandlal Nagori Rajendra
Chauhan Bhaskar
Singh YADAV Dharmvir
Kumar Sharma Avadhesh
Kumar Yatendra
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2017013433A publication Critical patent/MX2017013433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Composiciones farmacéuticas que comprenden cefepima o una sal farmacéuticamente aceptable del mismo, tazobactam o una sal farmacéuticamente aceptable del mismo, y arginina o una sal farmacéuticamente aceptable del mismo; y se describe su uso en el tratamiento, control o prevención de la infección bacteriana.
MX2017013433A 2016-03-31 2017-03-31 Composiciones antibacterianas. MX2017013433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621011249 2016-03-31
PCT/IB2017/051872 WO2017168394A1 (en) 2016-03-31 2017-03-31 Antibacterial compositions

Publications (1)

Publication Number Publication Date
MX2017013433A true MX2017013433A (es) 2018-01-30

Family

ID=58664746

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013433A MX2017013433A (es) 2016-03-31 2017-03-31 Composiciones antibacterianas.

Country Status (12)

Country Link
US (1) US20180064691A1 (es)
EP (1) EP3268001A1 (es)
JP (1) JP2018516953A (es)
KR (1) KR20180125866A (es)
CN (1) CN107847502A (es)
AU (1) AU2017242135A1 (es)
BR (1) BR112017022864A2 (es)
CA (1) CA2983256A1 (es)
MX (1) MX2017013433A (es)
RU (1) RU2017144216A (es)
WO (1) WO2017168394A1 (es)
ZA (1) ZA201706948B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905979T3 (es) * 2016-03-31 2022-04-12 Wockhardt Ltd Composiciones antibacterianas
EP3268002B8 (en) * 2016-03-31 2020-10-28 Wockhardt Bio AG Antibacterial compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010862T2 (de) * 2003-04-14 2009-01-02 Wyeth Holdings Corp. Zusammensetzungen enthaltend Piperacillin und Tazobactam zur Injektion
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
WO2007075452A2 (en) * 2005-12-16 2007-07-05 Wyeth Lyophilized compositions of a triazolopyrimidine compound
EP2015755A4 (en) * 2006-04-28 2010-02-24 Wockhardt Ltd ENHANCED TREATMENT FOR TREATING BACTERIAL RESISTANT INFECTIONS
MX356373B (es) * 2011-05-28 2018-05-25 Wockhardt Ltd Composiciones que comprenden un agente antibacterial y tazobactam.
CN102743388B (zh) * 2012-05-15 2014-05-28 南京优科生物医药有限公司 一种抗产生β内酰胺酶细菌的组合物
BR112015006868B1 (pt) * 2012-09-27 2021-11-30 Merck Sharp & Dohme Corp Composição farmacêutica de tazobactam-arginina cristalina e composto beta-lactâmico, seu uso, método para fazer uma composição farmacêutica e uso de tazobactam-arginina cristalina e de composto beta-lactâmico
AU2014227660B2 (en) * 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions

Also Published As

Publication number Publication date
KR20180125866A (ko) 2018-11-26
RU2017144216A (ru) 2019-06-18
US20180064691A1 (en) 2018-03-08
WO2017168394A1 (en) 2017-10-05
ZA201706948B (en) 2019-02-27
BR112017022864A2 (pt) 2018-07-17
CA2983256A1 (en) 2017-10-05
CN107847502A (zh) 2018-03-27
EP3268001A1 (en) 2018-01-17
AU2017242135A1 (en) 2017-11-02
JP2018516953A (ja) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2015015506A (es) Peptidos antimicrobianos.
EP3607952A4 (en) USE OF CARRIMYCIN AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF TUMORS
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
BR112017002335A2 (pt) formulações de suspensão oral em pó de agentes antibacterianos
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017013433A (es) Composiciones antibacterianas.
MX2018000092A (es) Nuevo lipolantipeptido biciclico, preparacion y uso como agente antimicrobiano.
PH12018501758A1 (en) Oritavancin formulations
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2017013434A (es) Composiciones antibacterianas.
MX2018011095A (es) Compuestos de carbapenem.
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MY186775A (en) Antibacterial compositions and methods
EP3691665A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A PROBIOTIC AND A PREBIOTIC FOR PREVENTING OR TREATING DRUG-RESISTANT INFECTIONS
MX2019010112A (es) Compuestos antibacterianos.
PH12016502548A1 (en) Antimicrobial compositions with effervescent agents
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
UA94988U (xx) Фармацевтична композиція
UA111961U (uk) Антибактеріальна композиція